ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2017
Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.
Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04466267 (The Molecular Mechanism of RAS Wild-type Metastatic Colorectal Cancer), which is not on this map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Molecular Mechanism of RAS Wild-type Metastatic Colorectal Cancer (mCRC) Resistance to Anti Epidermal Growth Factor Receptor (EGFR) Antibody
Who cites it
39 citing papers in PubMed, 73 citations in OpenAlex.
- Revolutionizing lung cancer screening: the rise of artificial intelligence integrating circulating tumor markers.World journal of surgical oncology · 2026Review
- Circulating exosomal miR-17-92 cluster serves as a novel noninvasive diagnostic marker for patients with gastric cancer.World journal of gastrointestinal oncology · 2025Article
- Cholangiocarcinoma: The era of liquid biopsy.World journal of gastroenterology · 2025Review
- From photonic technologies to microfluidics-A review on the techniques which revolutionize liquid biopsy, opening a new era in cancer therapy.Health science reports · 2024Article
- Advances in circulating tumor cells for early detection, prognosis and metastasis reduction in lung cancer.Frontiers in oncology · 2024Review
- Review
- Value of peripheral blood circulating tumor cell detection in the diagnosis of thoracic diseases and the prediction of severity.Clinical and experimental medicine · 2023Article
- Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing.JCO precision oncology · 2023Article
- Article
- Brain metastases and lung cancer: molecular biology, natural history, prediction of response and efficacy of immunotherapy.Frontiers in immunology · 2023Review
- Technologies and applications of single-cell DNA methylation sequencing.Theranostics · 2023Review
- Review
- From COPD to Lung Cancer: Mechanisms Linking, Diagnosis, Treatment, and Prognosis.International journal of chronic obstructive pulmonary disease · 2022Review
- Circular RNAs as diagnostic biomarkers for gastric cancer: A comprehensive update from emerging functions to clinical significances.Frontiers in genetics · 2022Review
- Liquid Biopsy-Based Colorectal Cancer Screening via Surface Markers of Circulating Tumor Cells.Diagnostics (Basel, Switzerland) · 2021Review
- Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring.International journal of molecular sciences · 2021Review
- Review
- When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review.Oncology and therapy · 2021Review
- Liquid biopsy in cholangiocarcinoma: Current status and future perspectives.World journal of gastrointestinal oncology · 2021Review
- Exploration of Circulating Tumour Cell (CTC) Biology: A Paradigm Shift in Liquid Biopsy.Indian journal of clinical biochemistry : IJCB · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Current trajectory of clinical care is heading in the direction of personalized medicine. In an ideal scenario, clinicians can obtain extensive diagnostic and prognostic information via minimally-invasive assays. Information available in the peripheral blood has the potential to bring us closer to this goal. In this review we highlight the contributions of circulating tumor cells and circulating tumor DNA and RNA (ctDNA/ctRNA) towards cancer therapeutic field. We discuss clinical relevance, summarize available and upcoming technologies, and hypothesize how future care could be impacted by a combined study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.